Description: Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
Home Page: www.sprintbioscience.com
Novum
Huddinge,
141 57
Sweden
Phone:
46 84 11 44 55
Officers
| Name | Title |
|---|---|
| Mr. Erik Kinnmann Assoc. Prof., M.B.A., M.D., Ph.D. | Chief Exec. Officer |
| Prof. Pär Nordlund | Founder |
| Dr. Martin Andersson | Co-Founder & Chief Scientific Officer |
| Ms. Jessica Martinsson MSc | Founder & COO |
| Dr. Kenth Hallberg | Founder & Director of Structural Chemistry |
| Mr. Mathias Skalmstad | Chief Financial Officer |
| Ms. Anne-Marie Wenthzel | Chief Bus. Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6083 |
| Price-to-Sales TTM: | 27.0919 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |